Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Mastocytosis is a myeloid neoplasm characterized by abnormal accumulation and frequent activation of mast cells (MCs) in various organs. Organ systems typically involved are the bone marrow, skin, liver and gastrointestinal tract. In most adult patients, the systemic form of mastocytosis (SM) is diagnosed, which includes an indolent subvariant, an aggressive subvariant and a leukemic subvariant, also termed MC leukemia. Whereas in pediatric mastocytosis, which is usually confined to the skin, a number of different KIT mutations and other defects may be detected, the KIT mutation D816V is detectable in most (adult) patients with SM. In a subset of these patients, additional oncogenic factors may lead to enhanced survival and growth of MCs and, thus, to advanced SM. Other factors may lead to MC activation, with consecutive anaphylactic reactions that can be severe or even fatal. Treatment of SM usually focuses on symptom relief by histamine receptor antagonists and other supportive therapy. However, in aggressive and leukemic variants, cytoreductive and targeted drugs must be applied. Unfortunately, the prognosis in these patients remains poor, even when treated with novel KIT-targeting agents, polychemotherapy or stem cell transplantation. This article provides a summary of our knowledge on the pathogenesis and on treatment options in SM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis
Schwartz, L. B., Metcalfe, D. D., Miller, J. S., Earl, H., & Sullivan, T. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706253162603 · Cited by 784
Mast cells are essential intermediaries in regulatory T-cell tolerance
Lu, L.-F., Lind, E. F., Gondek, D. C., Bennett, K. A., Gleeson, M. W., Pino-Lagos, K., Scott, Z. A., Coyle, A. J., Reed, J. L., Van Snick, J., et al. (2006) · Nature · doi:10.1038/nature05010 · Cited by 751
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750
Self-citationMetcalfe, D. D. (2008) · Blood · doi:10.1182/blood-2007-11-078097 · Cited by 536
Valent, P., Spanblochl, E., Sperr, W., Sillaber, C., Zsebo, K., Agis, H., Strobl, H., Geissler, K., Bettelheim, P., & Lechner, K. (1992) · Blood · doi:10.1182/blood.v80.9.2237.2237 · Cited by 439
Self-citationMasitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT
Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Castéran, N., Borge, L., Hajem, B., Lermet, A., Sippl, W., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007258 · Cited by 421
Self-citationBodemer, C., Hermine, O., Palmérini, F., Yang, Y., Grandpeix-Guyodo, C., Leventhal, P. S., Hadj-Rabia, S., Nasca, L., Georgin-Lavialle, S., Cohen-Akenine, A., et al. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.281 · Cited by 397
Self-citationSperr, W. R., Jordan, J.-H., Fiegl, M., Escribano, L., Bellas, C., Dirnhofer, S., Semper, H., Simonitsch-Klupp, I., Horny, H.-P., & Valent, P. (2002) · International Archives of Allergy and Immunology · doi:10.1159/000059404 · Cited by 207
Self-citationTryptase, a mediator of human mast cells
Schwartz, L. B. (1990) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(05)80222-2 · Cited by 129
Cited by
Stem Cell Factor Receptor/c-Kit: From Basic Science to Clinical Implications
Lennartsson, J., & Rönnstrand, L. (2012) · Physiological Reviews · doi:10.1152/physrev.00046.2011 · Cited by 825
Valent, P., Akin, C., Arock, M., Brockow, K., Butterfield, J. H., Carter, M. C., Castells, M., Escribano, L., Hartmann, K., Lieberman, P., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000328760 · Cited by 654
Self-citationMastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
Valent, P., Akin, C., & Metcalfe, D. D. (2017) · Blood · doi:10.1182/blood-2016-09-731893 · Cited by 592
Self-citationHistamine and H1-antihistamines: Celebrating a century of progress
Simons, F. E. R., & Simons, K. J. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.09.005 · Cited by 541
Arock, M., Sotlar, K., Akin, C., Broesby-Olsen, S., Hoermann, G., Escribano, L., Kristensen, T. K., Kluin-Nelemans, H. C., Hermine, O., Dubreuil, P., et al. (2015) · Leukemia · doi:10.1038/leu.2015.24 · Cited by 290
Self-citationValent, P., Escribano, L., Broesby‐Olsen, S., Hartmann, K., Grattan, C., Brockow, K., Niedoszytko, M., Nedoszytko, B., Oude Elberink, J. N. G., Kristensen, T., et al. (2014) · Allergy · doi:10.1111/all.12436 · Cited by 174
Self-citationMast cell activation syndromes: definition and classification
Valent, P. (2013) · Allergy · doi:10.1111/all.12126 · Cited by 120
Self-citationDigital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis
Greiner, G., Gurbisz, M., Ratzinger, F., Witzeneder, N., Simonitsch-Klupp, I., Mitterbauer-Hohendanner, G., Mayerhofer, M., Müllauer, L., Sperr, W. R., Valent, P., et al. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.277897 · Cited by 83
Midostaurin: a magic bullet that blocks mast cell expansion and activation
Valent, P., Akin, C., Hartmann, K., George, T. I., Sotlar, K., Peter, B., Gleixner, K. V., Blatt, K., Sperr, W. R., Manley, P. W., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx290 · Cited by 79
Self-citationGülen, T., Hägglund, H., Dahlén, B., & Nilsson, G. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12410 · Cited by 75
Valent, P., Hartmann, K., Schwaab, J., Alvarez-Twose, I., Brockow, K., Bonadonna, P., Hermine, O., Niedoszytko, M., Carter, M. C., Hoermann, G., et al. (2022) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2022.03.007 · Cited by 72
Self-citationPeter, B., Winter, G. E., Blatt, K., Bennett, K. L., Stefanzl, G., Rix, U., Eisenwort, G., Hadzijusufovic, E., Gridling, M., Dutreix, C., et al. (2016) · Leukemia · doi:10.1038/leu.2015.242 · Cited by 63
Self-citationScoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin
Fuchs, D., Kilbertus, A., Kofler, K., von Bubnoff, N., Shoumariyeh, K., Zanotti, R., Bonadonna, P., Scaffidi, L., Doubek, M., Elberink, H. O., et al. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.12.022 · Cited by 30
Self-citationSerotonin and its 5-HT1 receptor in human mastocytosis
Ritter, M., El-Nour, H., Hedblad, M.-A., Butterfield, J. H., Beck, O., Stephanson, N., Holst, M., Giscombe, R., Azmitia, E. C., & Nordlind, K. (2012) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2011.651222 · Cited by 17
Metadata
- Authors
- Arock, M., & Valent, P.
- Venue
- Expert Review of Hematology
- Publisher
- Informa UK Limited
- Published
- 2010-08
- Volume
- 3
- Issue
- 4
- Pages
- 497-516
- ISSN
- 1747-4086 (ISSN-L)
- 1747-4094
- OpenAlex
- W2117137662
- Cited by
- 158
- References
- 9
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.